Patton Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Patton Fund Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-391	Closed	-$302K	–	391
2026 Q1	$302K	Buy	+391	New	+$299K	0.05%	161
2025 Q4	–	Sell	-400	Closed	-$225K	–	500
2025 Q3	$225K	Hold	400	–	–	0.04%	356
2025 Q2	$210K	Buy	+400	New	+$223K	0.05%	449
2023 Q3	–	Sell	-4,068	Closed	-$2.92M	–	93
2023 Q2	$2.92M	Sell	4,068 -275	-6%	-$212K	0.85%	49
2023 Q1	$3.57M	Buy	4,343 +1,008	+30%	+$760K	1.02%	15
2022 Q4	$2.41M	Buy	+3,335	New	+$2.46M	0.7%	47
2020 Q4	–	Sell	-2,864	Closed	-$1.6M	–	94
2020 Q3	$1.6M	Sell	2,864 -76	-3%	-$46.1K	0.87%	50
2020 Q2	$1.83M	Buy	+2,940	New	+$1.67M	1.07%	16

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Patton Fund Management's REGN Position: Q2 2026 in Review

Patton Fund Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 391 shares — an estimated $302K sold.

Patton Fund Management first reported a position in REGN in Q2 2020 and held it in 8 quarters. The position peaked at $3.57M in Q1 2023. 399 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Patton Fund Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Patton Fund Management sold 391 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $302K.
Patton Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Patton Fund Management's Regeneron Pharmaceuticals position peaked at $3.57M in Q1 2023.
399 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Patton Fund Management's 13F filing for Q2 2026, filed 13 Jul 2026.